AlphAIAlphAI — Financial news for AI agents
Stock

$ZOAR

Zoar Ltd

Price · $ZOARvia TradingView
AI sentiment · 7d1 articles
OCT 28net (bullish − bearish)NOV 3
Bullish
0
Neutral
1
Bearish
0
Insider · 30dAll trades →

No SEC Form 4 filings for $ZOAR in the last 30 days.

See all $ZOAR insider activity →
Top stories · $ZOARMore →
NOV 3·finanznachrichten.deMed

Impact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their Form F-4 registration statement for a business combination. The deal, pending shareholder and NYSE American approval, will result in a combined company operating as Zoar Limited (ZOAR). A special meeting for Impact stockholders is scheduled for November 13, 2026, to vote on the proposal.

SEP 16·finanznachrichten.de

Impact BioMedical, Inc.: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)

Impact Biomedical Inc. (IBO) filed a Form F-4 registration statement with the SEC for its proposed merger with Zoar Ltd. The merger, subject to regulatory and shareholder approvals, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. The completion depends on SEC approval, shareholder votes, and NYSE American listing.

ZOAR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning ZOAR (Zoar Ltd). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

What's driving ZOAR

  • Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their Form F-4 registration statement for a business combination. The deal, pending shareholder and NYSE American approval, will result in a combined company operating as Zoar Limited (ZOAR). A special meeting for Impact stockholders is scheduled for November 13, 2026, to vote on the proposal.

    finanznachrichten.de · Nov 3, 2026

  • Impact Biomedical Inc. (IBO) filed a Form F-4 registration statement with the SEC for its proposed merger with Zoar Ltd. The merger, subject to regulatory and shareholder approvals, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. The completion depends on SEC approval, shareholder votes, and NYSE American listing.

    finanznachrichten.de · Sep 16, 2026

AlphAI scores every news story that mentions ZOAR with an AI model for sentiment and relevance, and aggregates insider trades from Zoar Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ZOAR

Score
NOV 3$IBOMedfinanznachrichten.de

Impact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their Form F-4 registration statement for a business combination. The deal, pending shareholder and NYSE American approval, will result in a combined company operating as Zoar Limited (ZOAR). A special meeting for Impact stockholders is scheduled for November 13, 2026, to vote on the proposal.

2 min read
SEP 16$IBOMedfinanznachrichten.de

Impact BioMedical, Inc.: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)

Impact Biomedical Inc. (IBO) filed a Form F-4 registration statement with the SEC for its proposed merger with Zoar Ltd. The merger, subject to regulatory and shareholder approvals, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. The completion depends on SEC approval, shareholder votes, and NYSE American listing.

2 min read